{"doi":"10.1177/1087054710379737","title":"Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate","abstract":"<jats:p>Objective: Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal. This noninferiority meta-analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents. Method: Selection criteria included randomized, controlled design; duration 6 weeks; and assessment of ADHD Rating Scale–IV–Parent Version: Investigator Administered and Scored (ADHDRS) scores. Six-week response rates, defined as ≥40% reduction in ADHDRS total score, were compared using a noninferiority margin of −15%. Results: Seven studies met inclusion criteria ( N = 1,368). After 6 weeks, 53.6% (95% confidence interval [CI] 48.6%-58.4%) of atomoxetine-treated patients ( n = 811) had responded compared with 54.4% (47.6%-61.1%) for methylphenidate ( n = 557), with atomoxetine demonstrating noninferiority to methylphenidate (absolute difference −0.9%, 95% CI −9.2%-7.5%). Conclusion: After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents.</jats:p>","journal":"Journal of Attention Disorders","year":2011,"id":589239,"datarank":3.723401140709779,"base_score":4.189654742026425,"endowment":4.189654742026425,"self_citation_contribution":0.6284482113039639,"citation_network_contribution":3.094952929405815,"self_endowment_contribution":0.6284482113039639,"citer_contribution":3.094952929405815,"corpus_percentile":null,"corpus_rank":null,"citation_count":65,"citer_count":64,"citers_with_citation_signal":57,"citers_with_endowment":57,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1450146,"name":"Michael R. Kohn","orcid":"0000-0002-7151-2914","position":1,"is_corresponding":false},{"id":1507563,"name":"Ruth Dickson","orcid":null,"position":2,"is_corresponding":false},{"id":1507564,"name":"Richard J. Walton","orcid":null,"position":3,"is_corresponding":false},{"id":1507565,"name":"Renee E. Granger","orcid":null,"position":4,"is_corresponding":false},{"id":1507566,"name":"Gregory W. van Wyk","orcid":null,"position":5,"is_corresponding":false},{"id":1507562,"name":"Philip L. Hazell","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate","abstract":"<jats:p>Objective: Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal. This noninferiority meta-analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents. Method: Selection criteria included randomized, controlled design; duration 6 weeks; and assessment of ADHD Rating Scale–IV–Parent Version: Investigator Administered and Scored (ADHDRS) scores. Six-week response rates, defined as ≥40% reduction in ADHDRS total score, were compared using a noninferiority margin of −15%. Results: Seven studies met inclusion criteria ( N = 1,368). After 6 weeks, 53.6% (95% confidence interval [CI] 48.6%-58.4%) of atomoxetine-treated patients ( n = 811) had responded compared with 54.4% (47.6%-61.1%) for methylphenidate ( n = 557), with atomoxetine demonstrating noninferiority to methylphenidate (absolute difference −0.9%, 95% CI −9.2%-7.5%). Conclusion: After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents.</jats:p>","is_dataset_classified":null,"base_score":4.189654742026425,"endowment":4.189654742026425,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20837981","pmcid":null,"openalex_id":"https://openalex.org/W2048386311","authors":[],"funders":[],"total_grants":0,"fwci":3.6701,"citation_percentile":0.93238902,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":15},{"year":2014,"count":5},{"year":2015,"count":11},{"year":2016,"count":8},{"year":2017,"count":5},{"year":2018,"count":1},{"year":2019,"count":2},{"year":2020,"count":3},{"year":2021,"count":2},{"year":2022,"count":1},{"year":2023,"count":2},{"year":2024,"count":2},{"year":2025,"count":1}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.1177/1087054710379737","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/full-xml/10.1177/1087054710379737","host_type":"publisher"},{"url":"https://doi.org/10.1177/1087054710379737","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20837981","host_type":"repository"}],"fields_of_study":["Attention Deficit Hyperactivity Disorder","Neurotransmitter Receptor Influence on Behavior","Neuroethics, Human Enhancement, Biomedical Innovations"],"mesh_terms":["Atomoxetine Hydrochloride","Adolescent","Central Nervous System Stimulants","Attention Deficit Disorder with Hyperactivity","Child","Female","Humans","Male","Methylphenidate","Propylamines","Randomized Controlled Trials as Topic","Treatment Outcome"],"keywords":["Atomoxetine","Methylphenidate","Psychology","Confidence interval","Atomoxetine hydrochloride","Attention deficit hyperactivity disorder","Randomized controlled trial","Psychiatry","Medicine","Internal medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-23T15:00:05.594335Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}